Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib With Tacrolimus/Methotrexate for GVHD Prophylaxis in Pediatric and Young Adult HCT Patients
NCT06128070Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Aug 2024
- Primary completion
- Nov 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in graft-versus-host disease (GVHD), sponsored by City of Hope. Started Aug 2024; status: recruiting.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06128070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06128070.